中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

4 records (took 0.012 seconds)

    MARKER FOR PREDICTING TUMOR REACTIVITY OF LYMPHOCYTES, AND USE THEREOF
    1.
    发明申请
    MARKER FOR PREDICTING TUMOR REACTIVITY OF LYMPHOCYTES, AND USE THEREOF 有权

    公开(公告)号：US20220251652A1

    公开(公告)日：2022-08-11

    申请号：US17436948

    申请日：2020-03-06

    Applicant: NEOGENTC CORP.

    Inventor： Hee Jin Lee ,  Gyungyub GONG ,  Hee Jae Lee ,  Jeong Han Seo ,  Gyeongback Lim

    IPC: C12Q1/6881 ,  C12Q1/6886

    Abstract: The present invention relates to a marker for predicting a tumor reactivity of lymphocytes, a composition for predicting a tumor reactivity, and a method for predicting a tumor reactivity. Using the genetic marker according to the present invention, a predictive model that can predict the tumor reactivity of cultured lymphocytes may be constructed, and it is possible to more accurately select tumor-specific lymphocytes to produce an effective immunotherapeutic agent, by predicting the reactivity of the lymphocytes through the present invention. In addition, by using the above genetic markers, it is possible to more conveniently and non-invasively separate lymphocytes from body tissues, blood, or body fluids, deviating from the conventional invasive methods, and to select only lymphocytes with tumor-specific activity, for immunotherapy. It is expected to widely use with various application.

    TRANSPOSON SYSTEM AND USES THEREOF
    3.
    发明公开
    TRANSPOSON SYSTEM AND USES THEREOF 审中-公开

    公开(公告)号：US20240327861A1

    公开(公告)日：2024-10-03

    申请号：US18577850

    申请日：2022-07-11

    Applicant: NEOGENTC CORP.

    Inventor： Chae Lyul LIM ,  Young-Ae KIM ,  Jiwon CHUNG ,  Seeun PARK

    IPC: C12N15/85 ,  C12N9/12

    CPC classification number: C12N15/85 ,  C12N9/1241 ,  C12N2830/50

    Abstract: The present invention relates to a transposon vector, a transposon system comprising same, a transposon kit, a cell into which the transposon vector is inserted, and uses thereof, wherein the present invention has been completed by confirming that an exogenous gene is effectively transferred into the chromosome of a target cell to produce a high yield of genetically modified cells. In particularly, it was confirmed that the transposon according to the present invention can effectively transfer a TCR or CAR-encoding gene to immune cells, and cells expressing the TCR or CAR show high reactivity to an antigen, and thus, it is expected that various TCR-T cells and CAR-T cells can be produced by using the transposon system according to the present invention. In particular, CAR-T cells with a high yield can be obtained at a low cost by using the transposon of the present invention, such that the prices of therapeutics can be lowered by lowering the production costs of CAR-T cellular therapeutic agents, whereas conventional CAR-T cells require high costs for the production of CAR as well as transfer to target cells. Moreover, it was confirmed that the transposon of the present invention can effectively transfer an antibody gene, such as an oncovirus-targeting neutralizing antibody, to HEK293 cells used for mass production of antibodies, such that various antibodies can easily be mass-produced by means of the transposon of the present invention In particular, since the transposon according to the present invention is not limited in the type of gene that can be transferred as a vector, it is expected that the transposon can be actively utilized according to various purposes in the development of genome-modified cell lines expressing various genes in addition to antibody genes.

Patent Agency Ranking